KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Free Cash Flow (2016 - 2025)

AbbVie (ABBV) has disclosed Free Cash Flow for 14 consecutive years, with $4.9 billion as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 27.65% to $4.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.8 billion through Dec 2025, changed 0.09% year-over-year, with the annual reading at $17.8 billion for FY2025, 0.09% changed from the prior year.
  • Free Cash Flow for Q4 2025 was $4.9 billion at AbbVie, down from $6.6 billion in the prior quarter.
  • The five-year high for Free Cash Flow was $7.7 billion in Q3 2021, with the low at $1.4 billion in Q1 2025.
  • Average Free Cash Flow over 5 years is $5.2 billion, with a median of $4.9 billion recorded in 2021.
  • The sharpest move saw Free Cash Flow tumbled 66.94% in 2024, then soared 140.59% in 2025.
  • Over 5 years, Free Cash Flow stood at $4.9 billion in 2021, then skyrocketed by 47.61% to $7.2 billion in 2022, then plummeted by 36.96% to $4.5 billion in 2023, then surged by 48.57% to $6.8 billion in 2024, then decreased by 27.65% to $4.9 billion in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $4.9 billion, $6.6 billion, and $4.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.